Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals are seeking the FDA's approval for Nexavar tablets for the treatment of patients with liver cancer.
Subscribe to our email newsletter
Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.
The companies also confirmed that they are planning a company-sponsored phase III study of Nexavar in the adjuvant treatment of hepatocellular carcinoma (HCC) following the complete removal of early stage liver cancer.
A previous clinical trial demonstrated that Nexavar extended overall survival by 44% in patients with HCC versus placebo.